2 results
Approved WMOCompleted
- To compare the primary pharmacokinetic parameters AUC0-last, AUC0-*, and Cmax of MK-8228 after single dose administration of one tablet of 480 mg MK-8228 (test) and two tablets of 240 mg MK-8228 (reference) under fasting conditions.- To compare…
Approved WMORecruiting
The rationale for conducting the PARADIGM study is to evaluate the safety and effectiveness of the AVP III for closure of PVLs. Until recently, current treatment in the US and OUS included off-label use of various occluder devices. The study will…